TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the University of Connecticut where he was a practicing oncologist for many years.

“We are ecstatic that Dr. Langsam is joining our already impressive group of clinical leaders at TOI as our next CCO.” said Daniel Virnich, CEO of The Oncology Institute. “As we see acceleration in new value-based partnerships across the country and growth in our MSO model, Dr. Langsam’s deep expertise in Oncology and Specialty Pharmacy will be pivotal in scaling our therapeutic decision-making model across the enterprise and building a high-value engaged MSO network.”

“I couldn’t be more excited about joining the senior leadership team at TOI as CCO”, commented Dr. Langsam. “TOI has been leading value-based community oncology for many years, and acceleration in risk-based contracts and service offerings makes this a critical moment for the organization to continue scaling its clinical model to provide even greater benefits to patients and payor partners.”

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.

For more information, visit 

Contacts

Media

The Oncology Institute, Inc.

Investors

Solebury Strategic Communications





EN
14/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute Reports First Quarter 2025 Financial Results an...

The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in th...

 PRESS RELEASE

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Off...

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Direct...

 PRESS RELEASE

The Oncology Institute to Participate at the B. Riley Securities 25th ...

The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley’s 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering...

 PRESS RELEASE

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on H...

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting ...

 PRESS RELEASE

The Oncology Institute Announces First Quarter 2025 Earnings Release D...

The Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference Call CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch